MAPT and Alzheimer disease: Although there are additional tau drug discovery efforts ongoing at both the clinical and preclinical stages (25, 26), there would nonetheless be considerable value in identifying new drug targets and related small molecule modulators that would reduce the formation or persistence of misfolded tau species in AD and related tauopathies.